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OBJECTIVE — This meta-analysis reviews rates of progression of diabetic retinopathy
to proliferative diabetic retinopathy (PDR) and/or severe visual loss (SVL) and temporal
trends.
RESEARCH DESIGN AND METHODS — This systematic literature review and meta-
analysis of prospective studies assesses progression of retinopathy among diabetic patients
withouttreatmentforretinopathyatbaseline.Studiespublishedbetween1975toFebruary2008
were identiﬁed. Outcomes of interest were rates of progression to PDR and/or SVL. Pooled
baseline characteristics and outcome measures were summarized using weighted averages of
counts and means. Baseline characteristics and outcomes were compared between two periods:
1975–1985 and 1986–2008.
RESULTS — A total of 28 studies comprising 27,120 diabetic patients (mean age 49.8 years)
were included. After 4 years, pooled incidence rates for PDR and SVL were 11.0 and 7.2%,
respectively. Rates were lower among participants in 1986–2008 than in 1975–1985. After 10
years, similar patterns were observed. Participants in 1986–2008 studies had lower proportions
of PDR and non-PDR at all time points than participants in 1975–1985 studies.
CONCLUSIONS — Since1985,diabeticpatientshavelowerratesofprogressiontoPDRand
SVL. These ﬁndings may reﬂect an increased awareness of retinopathy risk factors; earlier
identiﬁcation and initiation of care for patients with retinopathy; and improved medical man-
agement of glucose, blood pressure, and serum lipids. Differences in baseline characteristics,
particularly in the prevalence and severity of retinopathy, could also have contributed to these
temporal differences.
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D
iabetes affects more than 170 mil-
lion individuals worldwide (1,2),
anddiabeticretinopathyisthemost
frequent cause of visual impairment
among working-age individuals (3,4). In
the last 3 decades, a relative decline in
ratesofdiabeticretinopathyhasbeensug-
gestedbysomestudies,(5–8)possiblyre-
ﬂecting improved patient and physician
awareness, screening, and prevention, as
wellasbettermanagementofdiabetes(9).
In 1985, the Early Treatment Diabetic
Retinopathy Study (ETDRS) demon-
strated the effectiveness of laser photoco-
agulation (10,11). Systemic control of
both hyperglycemia and hypertension
was shown to be important in the Diabe-
tes Control and Complications Trial
(DCCT) and the UK Prospective Diabetes
Study (UKPDS) in the 1990s (12,13).
Findings from these trials, other studies,
and clinical practice guidelines may have
led to increased public awareness to dia-
betes risk factors and a shorter time from
onsettodiagnosis,potentiallyalteringthe
rates of diabetic retinopathy progression
(9,14).
Understanding the natural history of
diabetic retinopathy is also important for
estimating sample size for testing new in-
terventions in clinical trials. Already, in-
adequate sample size estimations may
have resulted in underpowered trials
(15). Traditionally, progression rates
from the ETDRS and the Wisconsin Epi-
demiologicStudyofDiabeticRetinopathy
(WESDR) were used for sample size cal-
culations (16–22). However, these stud-
ies were conducted almost 30 years ago.
Contemporary estimates for diabetic reti-
nopathy progression are clearly needed,
some of which may, in part, be provided
by more recent studies, such as the Daily-
DoseConsensusInterferonandRibavirin:
Efﬁcacy of Combined Therapy (DIRECT)
trial (23,24).
In this systematic review and meta-
analysis, we summarized the best avail-
able evidence to provide contemporary
data on the clinical course of diabetic ret-
inopathy and to examine potential differ-
ences in rates of diabetic retinopathy
progression over time.
RESEARCH DESIGN AND
METHODS— We conducted a sys-
tematic review and meta-analysis on the
clinical course of diabetic retinopathy fo-
cusing primarily on two outcomes: 1)
progression to proliferative diabetic reti-
nopathy (PDR) and 2) progression to se-
vere visual loss (SVL), deﬁned as log–
minimum angle of resolution (MAR)
visual acuity (VA) 1.0 (deﬁned as VA
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studies
All studies published in English, French,
German, Spanish, Italian, and Portuguese
assessing the progression of diabetic reti-
nopathy among patients with diabetes
were included. Eligible studies included
patients without and with diabetic reti-
nopathy who had not received any
speciﬁc ocular treatment for diabetic
retinopathy(includingphotocoagulation,
vitrectomy, and intravitreal injections).
Among included studies were the control
arms of clinical trials for treatment-naïve
patients assessed for diabetic retinopathy
progression. We allowed study samples
with up to 15% of patients in control
groups to receive laser or other diabetic
retinopathy–speciﬁc treatment.
We searched MEDLINE, Current
Contents, and the Cochrane Library for
published studies from January 1975
through 20 February 2008. Search terms
used included: “diabetes mellitus OR dia-
bet*ORdiabetesORinsulin*ORdiabetic
retinopathy” and “diabetic maculopathy
OR macular edema, cystoid OR edema
OR macul* OR exudate OR laser coagu-
lationORphotocoagulat*ORvitrect*OR
intravitr* OR triamcinolone.” The use of
medical subject headings (MeSH) terms
and text words (or equivalent) in the ap-
propriate syntax of each database were
applied. We also reviewed PubMed for
the 6 months prior to the search date (20
August 2007 through 20 February 2008)
with no limits and Current Contents for
the year prior to the search date (20 Feb-
ruary 2007 through 20 February 2008).
Additionally, manual reference checks
were performed of bibliographies of arti-
cles and reviews published within the last
5 years (2004–2008).
Selection of studies
We selected prospective interventional or
observational studies reporting the pro-
gression of diabetic retinopathy to PDR
and/or progression to SVL at 4-, 5-, and




tients not yet treated for diabetic
retinopathy (i.e., treatment naïve) fol-
lowed for at least 1 year, diabetic retinop-
athy assessed using retinal photography
and/or ﬂuorescein angiography, and cat-
egorized using the modiﬁed ETDRSDR
severity grades: grade 1 (no diabetic reti-
nopathy), grades 2 and 3 (nonprolifera-
tive diabetic retinopathy [NPDR]), and
grade 4 (PDR).
Intheinitialscreening,abstractswere
reviewed by a single reviewer for obvious
exclusion criteria. Full publications were
retrieved for all citations accepted at the
initial screening. The complete studies
were then rescreened and reviewed by
two investigators based on prospective
protocol, with discrepancies resolved by
consulting a third investigator. Studies
were assigned a level of evidence using
criteria from the Centre for Evidence-
based Medicine in Oxford, U.K. (CEBM).
Data collection and deﬁnition
The study, patient, and treatment data
were extracted. If necessary, contact and
clariﬁcation was made with authors of ac-
cepted studies for speciﬁc data and anal-
yses. VA assessments for baseline
characteristics were reported as best-
corrected distance VA. When reported,
logMAR VA was preferentially extracted.
Conversions between logMAR and
Snellen values were performed using pre-
viously reported methods (The MNREAD
Acuity Chart), with logMAR 0.0 corre-
sponding to 20/20 Snellen and 1.0 corre-
sponding to 20/200 Snellen. LogMAR
values were then categorized into 0.0,
0.00–0.48, 0.48–1.0, and 1.0.
Data analysis
Outcome measures were estimated from
the pooled data. Studies were stratiﬁed
into two time periods (deﬁned by start
date of patient accrual)—1975–1985 and
1986–2008—with the 1985 cutoff se-
lected to coincide with publication of
ETDRS(19).Pooledbaselinecharacteristics
and outcome measures were summarized
using weighted averages of counts, pro-
portions, and means. Weighted average
proportions were reported as percent-
ages, whereas weighted means were re-
ported with ranges. The number of
patients enrolled was used to calculate
study and patient demographics. For
some studies, the number of eyes was
used as the denomination; however,
when only patient numbers were re-
ported, it was assumed that only one eye
per patient was studied. Meta-analyses
wereperformedtopoolwithin-studyout-
come measures. For efﬁcacy outcomes of
interest(PDRandSVL),meta-analysesfor
proportions with 95% CIs were per-
formed across the studies using both
ﬁxed-effects (25,26) and restricted-
maximum likelihood random-effects
(27,28) models. Heterogeneity between
studies was measured using the Cochran
Q statistic for heterogeneity. For continu-
ous outcomes, meta-analyses for means
with 95% CIs were performed. To ac-
count for variations in baseline severity,
analyses were stratiﬁed by baseline dia-
betic retinopathy status (no diabetic reti-
nopathy and any diabetic retinopathy).




Figure 1 shows the search yielded 3,130
abstracts screened for eligibility, of which
2,807 citations were rejected based on
obvious exclusion criteria. Full articles of
323 citations were retrieved, and 76 met
all eligibility criteria; 28 were primary
studies, and 48 were related publications
(same patient populations contributing
additional data, e.g., outcome data at dif-
ferent time points).
Supplemental Tables S2 and S3 list
study-level characteristics of the 28 in-
cluded studies. Of these, 14 were con-
ducted during 1975–1985 and the rest
during 1985–2008. Among the accepted
studies, different methods were used to
ascertain and classify diabetic retinopa-
thy, although many used the ETDRS se-
verity scale (29–31). Deﬁnitions for
vision loss also varied, with studies re-
portingVAchangeasVA2lineslost(or
10 ETDRS letters lost) or VA 3 lines lost
(or 15 ETDRS letters lost and doubling of
the visual angle).
Patient characteristics and reporting
patterns
The 28 studies enrolled 27,120 diabetic
patients assessed for diabetic retinopathy
atthe4-,5-,and10-yeartimepoints.The
mean patient age was 49 years, 46% were
female, 48% had type 2 diabetes, and the
mean diabetes duration was 11 years;
55% had no diabetic retinopathy at base-
line, whereas 59% had baseline logMAR
VA 0.0. Participants in 1986–2008 had
similarsexdistribution,agerange,anddi-
abetes duration as participants in 1975–
1985; however, studies in the ﬁrst time
period enrolled more patients with type 1
diabetes (supplemental Table S4).
Progression to PDR and SVL
Nearly 60% of included studies re-
portedprogressiontoPDR,and35%re-
ported progression to SVL. In contrast,
only 11% reported two-step and 4%
three-step progression of diabetic reti-
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threelineswasreportedin16and9%of
the included studies, respectively. Ta-
ble 1 shows the incidence of each end
point at the 4-, 5-, and 10-year time
points, both overall and within each
study period.
After 4 years, the pooled incidence of
PDR and SVL was 11.0 and 7.2%, respec-
tively.Table2showsthe4-,5-,and10-year
incidenceofPDRandSVLstratiﬁedfortime
period. For studies reporting outcomes af-
ter4years,19.5%ofpatientsin1975–1985
developed PDR compared with only 2.6%
in1986–2008.ForSVL,9.7%ofpatientsin
1975–1985 developed SVL compared with
3.2% in 1986–2008. Similar trends were
seen for 5- and 10-year outcomes. For ex-
ample, for studies reporting outcomes after
5 years, 18.0% of patients in 1975–1985
developed PDR versus 6.4% in 1986–
2008; for SVL, corresponding rates were
13.7 versus 3.6%, respectively. Of studies
reporting outcomes at 10 years, rates for
PDR were 11.5% in 1975–1985 versus
6.6% in 1986–2008; for SVL, corre-
sponding rates were 6.0 versus 2.6%,
respectively.
Table 3 shows that when stratiﬁed by
baseline diabetic retinopathy status, for
participants without diabetic retinopathy
at baseline, PDR developed in 6.3% dur-
ing 1975–1985 (two studies) compared
with 2.6% during 1986–2008 (ﬁve stud-
ies); similarly, 2.0% developed SVL in
1975–1985 compared with none in
1986–2008. For participants with dia-
betic retinopathy at baseline, PDR devel-
oped in 39.7% of patients in 1975–1985,
Figure 1—Selection of studies for systematic review.
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to PDR during 1986–2008; 17.5% pro-
gressed to SVL during 1975–1985 (two
studies),whereas5.4%progressedtoSVL
in 1986–2008 (one study).
CONCLUSIONS — This systematic
review and meta-analysis provides esti-
mates of the incidence of PDR and de-
velopment of SVL in patients who were
untreated for diabetic retinopathy at
baseline. Our analyses show that the
overall incidence of PDR and SVL ob-
served in studies after 1985 (e.g., 2.6%
for PDR and 3.2% for SVL at 4 years)
were substantially lower than rates ob-
served before 1985 (19.5% for PDR and
9.7% for SVL at 4 years). These ﬁndings
support our a priori hypothesis that
contemporary rates of progression to
PDR and SVL are substantially lower
and may reﬂect improvements in the
overall care and management of diabe-
tes and associated risk factors (e.g., hy-
perglycemia and hypertension) over
time,togetherwithearlieridentiﬁcation
of type 2 diabetes.
In terms of the principal risk factors
for diabetic retinopathy, studies in the
two time periods had relatively similar
baselinedurationofdiabetes:11.1years
for 1975–1985 versus 11.7 years for
1986–2008. However, in the later pe-
riod, substantially greater proportion of
participants had type 1 diabetes (71.1
versus 48.3%), which could partly ex-
plain lower rates of baseline NPDR and
PDR. Studies of type 2 diabetic patients
report only a nominal duration of dia-
betes because its onset is gradual. Thus,
an earlier diagnosis of type 2 diabetes
during1986–2008couldpartlyexplain
lowerbaselinediabeticretinopathydur-
ing this period. Differences in baseline
diabetic retinopathy severity between
the two time periods (less severe after
1985) could also explain lower rates of
progression to PDR and/or SVL after
1985.
Our review identiﬁed signiﬁcant
limitations in the literature. First, the
observed differences in progression
rates between the two periods were not
independent of the distribution of the
severity of diabetic retinopathy at base-
line. Studies conducted earlier had
largerproportionsofmoreadvanceddi-
abetic retinopathy at baseline, and pro-
gression rates between the two time
periods could not be formally compared
without appropriate adjustments. How-
ever,therewereinsufﬁcientstudiestoen-
able regression-based adjustments for
baseline severity. Thus, we chose to strat-
ify by baseline diabetic retinopathy sever-
ity, but even after stratiﬁcation, the
distribution of baseline diabetic retinopa-
thy severity was not sufﬁciently balanced.
Second, outcome reporting patterns var-
ied. Baseline VA and progression of vi-
sion-lossmeasurementsbythelossoftwo
and three lines (or equivalent) or diabetic
retinopathy progression by two- or three-
step progression (or equivalent) were re-
ported by only a few studies. The failure
toreportprogressionofvisuallosslimited
the ability to explore the impact of dia-
betic retinopathy progression before the
development of PDR or SVL. This may be
important because current recommenda-
tions for diabetic retinopathy clinical tri-
als emphasize the universal use of three-
step progression of diabetic retinopathy
as a disease progression marker at the
3-yeartimepoint(32).Athirdissuewas
the varying quality of diabetic retinop-
athy studies. We included only studies
of treatment-naïve patients in which
outcomes were reported separately by
diabetic retinopathy severity at baseline
and where diabetic retinopathy assess-
ment involved retinal photography
and/or ﬂuorescein angiography. Al-
though this improved comparability of
studies, it limited the pool of data for
analysis. Additionally, we included
both interventional and prospective ob-
servational studies covering a wide
range of study designs, sample sizes,
treatment settings, and study inclusion
criteria. Although these variations
could be of concern, the broader inclu-
sion reﬂected the diversity of diabetic
retinopathy studies in the literature. Fi-
nally, there were insufﬁcient data on
ethnic composition or socioeconomic
statustodeterminewhetherratesvaried
by these factors.
Because the availability of numer-
ous treatment modalities would make a
new prospective study of untreated pa-
tients impossible, our study provides
the best available evidence from the lit-
erature, even with the limitation that
exact underlying causes for the tempo-
ral differences cannot be fully ex-
plained. We identify several areas for
future research. First, based on baseline
diabetic retinopathy severity, research-
ers should consider contemporary rates
of progression to PDR and/or SVL in es-
timating sample sizes for clinical trials.
Second, future studies should report
Table 1—Incidence rates of outcomes after 4, 5, and 10 years
4 years 5 years 10 years
 % n  % n  % n
Incidence
PDR 9 8.7 4,352 12 15.6 7,204 5 17.6 2,129
SVL 5 10.0 3,271 6 7.4 9,468 6 2.5 9,689
DME 5 24.0 2074 5 12.0 2,430 4 18.6 2,173
Photocoagulation 2 8.2 2,780 6 7.8 5,948 3 9.7 4,091
Retinopathy
2-step progression 2 33.2 1,772 3 45.1 2,342 1 67.1 1,616
3-step progression — — — — — — — — —
VA progression
2 lines lost 1 2.8 174 3 18.1 623 — — —
3 lines lost 1 7.9 1,846 — — — 1 18.5 1,846
Data are  (number of studies), percent (proportion of patients with event at each time point), or n (total number of patients at risk at each time point). Diabetic
macular edema.
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inopathy (i.e., ETDRS scales) and VA
outcomes (e.g., logMAR VA categories
or number of logMAR lines) so that pro-
gression rates can be estimated consis-
tently. Third, there is a need for the
publication of data on treatment-naïve
patients with diabetic retinopathy from
larger population-based studies.
In conclusion, our systematic re-
view and meta-analysis in treatment-
naïve patients with diabetes covering
1975–2008 show that contemporary
rates of PDR and/or SVL are substan-
tially lower than rates observed before
1985.Differencesareexplained,inpart,
by baseline differences in diabetic reti-
nopathy severity, A1C, and possibly
blood pressure levels. Limitations from
the available literature data prevented
in-depth exploration as to exact causes
for these differences. Our analysis sup-
ports some studies that suggest chang-
ing patterns of care for diabetes,
including earlier identiﬁcation and ini-
tiation of care along with attention to
appropriate management of diabetic




(%) Mean (95%CI)  n/N
Meta-analyzed
(%) Mean (95%CI)
Baseline distributions, 4 years
GHb (%) 1 2,366 11.7 (10.2–13.2) 4 795 8.4 (7.3–9.5)
Systolic blood pressure
(mmHg) 1 2,366 136.0 (114.4–157.6) 3 760 139.2 (127.4–151.1)
Diastolic blood pressure
(mmHg) 1 2,366 79.0 (78.6–79.5) 2 600 78.8 (73.1–84.5)
Retinopathy level (%)
No retinopathy 2 1,447/3,319 43.6 6 882/1,324 66.6
NPDR 4 1,693/3,604 47.0 6 271/1,324 20.5
PDR 4 460/3,604 12.8 6 42/1,324 3.2
Presence of DME (%) 2 602/1953 30.8 3 78/775 10.1
5-year incidence 4-year
incidence
PDR (%) 4 353/3,214 19.5 (2.4–36.6)* 5 26/1,138 2.6 (0.2–5.0)*
SVL (%) 3 320/2,967 9.7 (0.0–21.9)* 2 8/304 3.2 (0.0–9.2)*
Baseline distributions, 5 years
GHb (%) 3 7,295 9.3 (7.8–10.7) 2 2,245 8.0 (7.9–8.1)
Systolic blood pressure
(mmHg) 1 133 150.0 (146.9–153.1) 2 171 136.1 (121.2–151.0)
Diastolic blood pressure
(mmHg) 1 133 93.0 (91.3–94.7) 2 171 81.1 (78.1–84.1)
Retinopathy level (%)
No retinopathy 5 3,521/7,491 47.0 6 1,731/2,651 65.3
NPDR 6 3,387/7,702 44.0 6 762/2,651 28.7
PDR 6 787/7,702 10.2 6 138/2,651 5.2
Presence of DME (%) 3 3,134/5,664 55.3 4 222/2,516 8.8
5-year incidence
PDR (%) 6 1,046/5,153 18.0 (3.5–32.5)* 6 78/2051 6.4 (0.4, 12.4)*
SVL (%) 4 689/7,595 13.7 (0.9–26.5)* 2 14/1,873 3.60 (0.0, 11.4)*
Baseline distributions, 10 years
GHb (%) 4 9,777 9.3 (7.6–10.9) 3 796 8.2 (7.7–8.7)
Systolic blood pressure
(mmHg) 5 9,910 139.0 (129.3–148.7) 2 684 138.3 (127.3–149.2)
Diastolic blood pressure
(mmHg) 5 9,910 83.8 (78.6, 88.9) 2 684 81.5 (78.2, 84.8)]
Retinopathy level (%)
No retinopathy 6 5,733/9,939 57.7 3 526/796 66.1
NPDR 5 3,280/9,910 33.1 3 141/796 17.7
PDR 4 732/5,981 12.2 2 0/408 0.0
Presence of DME (%) 1 0/29 0.0 3 0/796 0.0
10-year incidence
PDR (%) 3 357/1,729 11.5 (0.0–25.7)* 2 17/400 6.6 (0.0, 18.3)*
SVL (%) 4 232/9,205 6.0 (0.9–11.1)* 2 11/484 2.6 (0.0–7.1)*
Data are  (number of studies), n (total number of patients at risk at each time point), percent, or mean (95% CI). *Heterogeneity by Cochran Q: P  0.05. DME,
diabetic macular edema.
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tially lower rates of diabetic retinopathy
progression and incident visual loss
over time (33,34).
Acknowledgments— The research was sup-
portedbyPﬁzer.T.Y.W.,R.K.,M.L.,H.F.,and
P.M. were paid consultants to Pﬁzer, and
M.M., M.H.-M., and G.R. were employees of
United BioSource Corporation (UBC) at the
time the research was conducted and the arti-
cle was developed. UBC is a consultancy
whoseactivitiesontheprojectwerefundedby
Pﬁzer. B.W. and A.P. are employees of Pﬁzer.
T.Y.W.hasbeenonadvisoryboardsforPﬁzer,
Allergan, and Novartis and has received hon-
oraria and travel and accommodation pay-
ments from them. He has also received
researchsupportfromPﬁzer.Hehasalsobeen
an investigator on clinical trials sponsored by
them and has received payments to support
the conduct of these trials. M.M. is employed
by UBC. He has also not been an investigator
on clinical trials sponsored by them and has
not received payments to support the conduct
of any trials. R.K. has been on advisory boards
for AstraZeneca, Eli Lilly, Novartis, and Pﬁzer
and has received honoraria and travel and ac-
commodation payments from them. As of 1
January 2007, the employer of M.L., the
GlostrupHospital,butnotM.L.receivesfund-
ingfromEliLilly,Novartis,CarlZeissMeditec,
Alcon, and Pﬁzer for contractual projects by
the Department of Ophthalmology involving
the effort of M.L. Under Danish government
policy, support for the costs of research, ad-
ministered by the institution, does not consti-
tute a conﬂict of interest. Before 1 January
2007, M.L. had personally administered con-
tractual and ﬁnancial relationships with the
above-mentioned companies. H.F. currently
serves on the Diabetic Retinopathy Clinical
Research network Data and Safety Monitoring
Committee (DSMC), Regeneron DSMC, and
Optimedica advisory board and is a paid con-
sultant to Pﬁzer, Alcon, Allergan, Ista, Eye-
tech, and Genentech. G.R. is employed by
UBC. She has also not been an investigator on
clinical trials sponsored by them and has not
received payments to support the conduct of
any trials. M.H.-M. is employed by UBC. She
has also not been an investigator on clinical
trials sponsored by them and has not received
payments to support the conduct of any trials.
B.W. is currently a paid employee of Pﬁzer.
Prior to her employment at Pﬁzer, she had
been a paid consultant and investigator on
clinical trials for Allergan. A.P. is a paid em-
ployee of Pﬁzer. P.M. has been on advisory
boards for Novartis, Pﬁzer, Allergan, and
Solvay and has received honoraria and travel
and accommodation payments from them. He
has also been an investigator on clinical trials
sponsored by these companies, as well as Eli
Lilly, and has received payments to support
the conduct of these trials. No other potential
conﬂictsofinterestrelevanttothisarticlewere
reported. The sponsor participated in the
study design, data analysis and interpretation,
andpreparationandreviewofthemanuscript.
T.Y.W. had full access to all the data in the
study and takes responsibility for the integrity
of the data and the accuracy of the data
analysis.









GHb (%) 1 2,366 11.7 (10.2–13.2) 3 635 9.2 (8.3–10.1)
Systolic blood pressure
(mmHg)
1 2,366 136.0 (114.4–157.6) 2 600 131.0 (113.4–148.7)
Diastolic blood pressure
(mmHg)
2,366 79.0 (78.6–79.5) 2 600 78.8 (73.1–84.5)
Retinopathy level (%)
No retinopathy 2 1,447/3,319 43.6 5 882/1,164 75.8
NPDR 2 1,529/3,319 46.1 5 237/1,164 20.4
PDR 2 339/3,319 10.2 5 33/1,164 2.8
Presence of DME (%) — — — 3 78/775 10.1
4-year incidence
PDR (%) 2 142/2,570 6.3 (1.6–10.9) 5 26/1,138 2.6 (0.2–5.0)
SVL (%) 1 41/1,823 2.0 (0.0–3.9) 1 0/174 0.0 (0.0–0.8)
Baseline distributions, any
retinopathy at baseline
GHb (%) — — — 1 160 7.1 (6.8–7.5)
Systolic blood pressure
(mmHg)
— — — 1 160 147.0 (144.2–149.8)
Diastolic blood pressure
(mmHg)
—— — — — —
Retinopathy level (%)
No retinopathy — — — 1 0/160 0.0
NPDR 2 164/285 57.5 1 34/160 21.3
PDR 2 121/285 42.5 1 9/160 5.6
Presence of DME (%) 2 602/1953 30.8 — — —
4-year incidence
PDR (%) 2 211/644 39.7 (21.2–58.3) — — —
SVL (%) 2 279/1,144 17.5 (0.0–38.1) 1 8/130 5.4 (0.0–15.1)
Data are  (number of studies), n (total number of patients at risk at each time point), percent, or mean (95% CI).
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